Our focus was on the effect of Bergacyn® on adipose tissue dysfunction, the main initiator of MS, and on the proliferation and differentiation of WAT and BAT, which are regulated by a complex network of transcriptional factors, with PPARγ being a key player in adipogenesis, lipid metabolism, and insulin sensitivity [42]. Here, INS is linked to myeloid sarcoma.